This is not the most recent version of the article. View current version (20 JAN 2010)

Intervention Review

You have free access to this content

Treatment of latent tuberculosis infection in HIV infected persons

  1. Jimmy Volmink2,
  2. Sara Woldehanna1,*

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 25 NOV 2003

DOI: 10.1002/14651858.CD000171.pub2

Database Title

Additional Information

How to Cite

Volmink J, Woldehanna S. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub2.

Author Information

  1. 1

    Academy for Educational Development, Center for Health Communication , Washington, DC, USA

  2. 2

    University of Stellenbosch, Faculty of Health Sciences, Tygerberg, South Africa

*Sara Woldehanna, Center for Health Communication , Academy for Educational Development, 1825 Connecticut Avenue NW, Washington, DC, 20009-5721, USA. swoldehanna@aed.org.

Publication History

  1. Publication Status: Unchanged
  2. Published Online: 7 OCT 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (20 Jan 2010)

View Full Article (HTML) Summary (59K)Standard (290K)Full (569K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Fitzgerald 2001 {published data only}
  • Fitzgerald DW, Severe P, Joseph P, Mellon LR, Noel E, Johnson WD, Pape JW. No effect of isonizid prophylazis for purified protein derivative-negative HIV infected adults living in a country endemic tuberculosis: results of a randomized trial. Journal of Acquuired Immune Deficiency Syndromes 2001;28(3):305-307.
Gordin 1997 {published data only}
  • Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, Klein M, Vaughn A, Besch CL, Perez G, Szabo S, El-Sadr W. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. NEJM 1997;337:315-320.
Gordin 2000 {published data only}
Halsey 1998 {published data only}
  • Halsey NE, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geitre L, Johnson E, Huebner R, Boulos R, Chaisson R. Randomized trial of isoniazid verusu risampicine and pyrazinamide for prevention of tuberculosis in HIV-1 infection. The Lancet 1998;351(9105):786-792.
Hawken 1997 {published data only}
  • Hawken MP, Meme HK, Elliot LC, Chakaya JM, Morris JS, Githui WA, Juma ES, Odhiambo JA, Thiong'o LN, Kimari JN, Ngugi EN, Bwayo JJ, Gilks CF, Plummer FA, Porter JDH, Nunn PP, McAdam KPWJ. Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: results of a randomized controlled trial. AIDS 1997;11:875-882.
Johnson 2001 {published data only}
  • Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-2147.
Johnson 2001 -anergy {published data only}
  • Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-2147.
Martinez 2001 {published data only}
  • Martinez AEM, Cuadra F, Solera J, Macia MA, Geijo P, Sanchez MPA, Rodriguez ZM, Largo J, Sepilveda MA, Rosa C, Sanchez L, Espinosa A, Mateos F, Blanch JJ. Evaluation of 2 tuberculosis chemoprohylaxis regimens in patients infected with human immunodeficiency virus. The Gecmei Group. Medicina Clinica (Barcelona) 2000;115(5):161-165.
Mwinga 1998 {published data only}
  • Mwinga A, Hosp M, Godfrey-Fusset P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, pobee J, Elliot AM, McAdam KPWJ, Porter JDH. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-57.
Pape 1993 {published data only}
Quigley 1998 {published data only}
  • Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, Godfrey-Fausett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian Adults. AIDS 2001;15:215-222.
Rivero 2002 {published data only}
  • Rivero A, Lopez-Cortes L, Castillo R, Lozano F, Gracia MA, Diez F, Escribano JC, Canueto J, Pasquau J, Hernandez JJ, Polo R, Martinez-Marcos FJ, Kindelan JM, Rey R. A randomized trial of 3 regimens to prevent tuberculosis in anergic patients infected with HIV. 9th Conf. of Retroviruses and Opportunistic Infections. 2002; Vol. Session 82:(Poster) 625-W.
Whalen 1997 {published data only}
  • Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ, Nsubuga P, Vjecha M, Myanja H, Kityo C, Loughlin A, Milberg J, Pekovic V. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. NEJM 1997;337:801-808.
Whalen 1997-anergy {published data only}
  • Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ, Nsubuga P, Vjecha M, Myanja H, Kityo C, Loughlin A, Milberg J, Pekovic V. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.. NEJM 1997;337:801-808.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Fitzgerald 2000 {published data only}
  • Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Pape JW. [Effect of post treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected indivduals: a randomized trial]. The Lancet 2000;356.
Garcia 1993 {published data only}
  • Gracia ML, Valdespino JL, Garcia-Sancho C, Weissenbacher M, Daniels E, peruga A, Palacios M, Loo E, Cruz C, Lina JL, Luna M, Mayar ME, Romero C, Pineda L, Sepulveda J. Compliance and side effects to chemoprophylaxis for TB in HIV+. Mexican experience. IX International Conference on AIDS. 1993; Vol. Abstract-Po-BO7-11.
Matteelli 1998 {published data only}
  • Matteelli A, Carosi G, Signorini L, Tebaldi A, Caligaris S, Gulletta M. Multinational study for preventive therapy of latent tuberculosis in HIV positive individuals: isoniazid vs. rifabutin. 12th World AIDS Conference. 1998; Vol. Abstract 60858.
Saenghirunvatta 1996 {published data only}
  • Saenghirunvattana S. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. J. Med Association Thai 1996;79(5).

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Sanchez 2002 {unpublished data only}
  • Sanchez F, Montse B, Herandez P, Lopez-Colomes JL, de Ollala PG, Garcia-Vidal J, Guerrero R. [Treatment of latent tuberculosis infection in injecting drug users co-infected by HIV]. Enf Emerg 2002;4(2):62-6.
Wadhawan 1993 {unpublished data only}
  • Wadhawan D, Hira S, Mwansa N, Sunkutu R, Adera T, Perine A. Preventive tuberculosis chemotherapy with isonizid (INH) among patients infected with HIV-1. IX International Conference on AIDS. 1993; Vol. Abstract PO-BO7-114.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
ATS 1990
  • American Thoracic Society (ATS). Medical Section of the American Lung Association. Diagnostic standards and classification of tuberculosis. Am Rev Resp Dis 1990;142.
Bocchino 2000
  • Bocchino M, Sanduzzi A, Bariffi F. Mycobactrtium tuberculosis and HIV co-infection in the lung: synergic immune dysregulation leading to disease progression. Mondaldi Arch Chest Dis 2000;55(5):381-8.
Bucher 1999
CDC 1998
  • CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998;47:1-51.
Cobo 2002
  • Cobo J, et al. Increased Risk of Tuberculosis Infection in HIV-Infected Patients with Severe Immunosuppression: a medical community response. Abstracts of the 9th Conference on Retrovirus and Opportunistic Infections. 2002.
Cohn 2000
  • Cohn D, El-Sadr WM. Treatment of latent tuberculosis infection. In: Sodeman WA Jr, Sodeman WA editor(s). Tuberculosis: A comprhensive international approach. Second Edition. New York: Marcel Decker, 2000:471-502.
Comsock 2000
  • Comsock G. Epidemiology of tuberculosis. In: Sodeman WA Jr, Sodeman WA editor(s). Tuberculosis: A comprhensive international approach. Second Edition. New York: Marcel Decker, 2000:129-156.
Comstock 1970
Daniel 2000
  • Daniel T, Boom WH, Ellner JJ. Immunology of Tuberculosis. In: Sodeman WA Jr, Sodeman WA editor(s). Tuberculosis: A comprhensive international approach. Second Edition. New York: Marcel Decker, 2000:187-214.
Dye 1999
Enarson 1994
  • Enarson DA, Rouillon A. The epidemiological basis of tuberculosis control. In: Davis PDO editor(s). Clinical tuberculosis. First Edition. London: Chapman & Hall, 1994:19-32.
Goletti 1996
Guelar 1993
Harries 1994
  • Harries AD. The association between HIV and tuberculosis in the developing world. In: Davis PDO editor(s). Clinical tuberculosis. First Edition. London: Chapman & Hall, 1994:241-264.
IUATCP 1982
  • International Union Against Tuberculosis Committee on Prophylaxis (IUATCP). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982;60:555-64.
Kovacs 2000
Narain 1992
Narita 1998
  • Narita M, Ashkin D, Hollender ES, Pitchenick AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
O'Brien 1994
  • O'Brien RJ. Preventive therapy for tuberculosis. In: Porter JDH, McAdam KPWJ editor(s). Tuberculosis: back to the future. Chichester: Wiley, 1994:151-66.
Peloquin 1996
  • Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30(9):919-25.
Piscitelli 2001
Selwyn 1989
Smieja 2003
  • Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). The Cochrane Library 2003, Issue 1. [Art. No.: CD001363. DOI: ]
Watkins 2000
WHO 1998
  • World Health Organization (WHO) and UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV: Report of a meeting held in Geneva, 18-20 February 1998. WHO/TB/98.255, UNAIDS/98.34.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Wilkinson 1998
View Full Article (HTML) Summary (59K)Standard (290K)Full (569K)